IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

被引：264

作者：

Finn, Richard S. ^{[1
]}

Qin Shukui ^{[2
]}

Ikeda, Masafumi ^{[3
]}

Galle, Peter R. ^{[4
]}

Ducreux, Michel ^{[5
]}

Kim, Tae-You ^{[6
]}

Lim, Ho Yeong ^{[7
]}

Kudo, Masatoshi ^{[8
]}

Breder, Valeriy Vladimirovich ^{[9
]}

Merle, Philippe ^{[10
]}

Kaseb, Ahmed Omar ^{[11
]}

Li Daneng ^{[12
,13
]}

Verret, Wendy ^{[14
]}

Shao Hui ^{[15
]}

Liu Juan ^{[15
]}

Li Lindong ^{[15
]}

Zhu, Andrew X. ^{[16
]}

Chen, Ann-Lii ^{[17
,18
]}

机构：

[1] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA

[2] Peoples Liberat Army Canc Ctr, Nanjing, Jiangsu, Peoples R China

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[4] Univ Med Ctr Mainz, Mainz, Germany

[5] Gustave Roussy Canc Ctr, Villejuif, France

[6] Seoul Natl Univ, Coll Med, Seoul, South Korea

[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[8] Kindai Univ, Fac Med, Osaka, Japan

[9] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[10] Univ Hosp La Croix Rousse, Lyon, France

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[12] City Hope Comprehens Canc Ctr, Duarte, CA USA

[13] Beckman Res Inst, Duarte, CA USA

[14] Genentech Inc, San Francisco, CA 94080 USA

[15] Roche Product Dev, Shanghai, Peoples R China

[16] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA

[17] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan

[18] Natl Taiwan Univ Hosp, Taipei, Taiwan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.267

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

267

引用

页数：2